Zeitschriftenartikel zum Thema „Sexual dysfunction, physiological – therapy“
Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Sexual dysfunction, physiological – therapy.
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Sexual dysfunction, physiological – therapy" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
1
Lukyantseva, G. V., und S. Y. Frank. „Possible applications of shock wave therapy in complex correction of sexual dysfunction in women“. HEALTH OF WOMAN, Nr. 9(135) (30.11.2018): 112–17. http://dx.doi.org/10.15574/hw.2018.135.112.
Der volle Inhalt der QuelleAnnotation:
In recent decades, interest in the quality of sexual life has significantly increased all over the world, not only among men but also among women, especially in low-birth-rate European countries. Improving this quality will not only resolve health issues in men and women, but will also improve the demographic situation in these countries. Scientific research in the field of both male and female sexual dysfunction is developing at a rapid pace. Both men and women go through the same phases of sexual reactions cycle: sexual desire, sexual arousal, and, as a result, orgasm and resolution phase. During the phase of sexual arousal, in both men and women, the blood flow to pelvic organs increases, but in the event of erectile dysfunction in men and frigidity in women, this process weakens or does not occur at all. Furthermore, the innervation of genital organs in male and female organisms is identical. Activation, which enables genital innervation, launches the activation of blood circulation in the target organs. Therefore, in case of ED in men, and in case of female sexual arousal disorder in women, along with other specific treatment methods, it is useful to perform non-invasive stimulation of insufficiently active physiological mechanisms of sexual arousal. However, for the treatment of ED in men, such stimulation has already been successfully used for a long time – that is the low-intensity extracorporeal shock wave therapy, which allows to restore the erection mechanism itself. Studies from throughout the world, including those conducted by Ukrainian scientists, have established that low-intensity extracorporeal shock wave therapy induces neovascularization and therefore improves blood circulation. The intensity of the basal and sexually stimulated genital blood flow is a necessary physiological tool of sexual arousal and orgasmic discharge, which makes the subject of artificial stimulation of this indicator by means of shock wave therapy in both men and women particularly important. The use of shock wave therapy can have a number of advantages not only due to the increased blood and lymph flow in the genitals, but also due to the powerful stimulation of the release of neurotransmitters and hormones which provide emotional coloring to the sexual feeling and increase libido (serotonin, dopamine, endorphins etc.). Therefore, along with combined therapy, the method of low-intensity extracorporeal shock wave therapy can be successfully used in the treatment of female sexual dysfunction. Key words: shock wave therapy, sexual dysfunction, female sexual arousal disorder, erectile dysfunction, DSM-5.
2
Bezkor, Mary F., und Angelo Canedo. „Physiological and psychological factors influencing sexual dysfunction in Multiple Sclerosis: Part 1“. Sexuality and Disability 8, Nr. 3 (September 1987): 143–46. http://dx.doi.org/10.1007/bf01376984.
Der volle Inhalt der Quelle
3
Starc, Andrej. „Clinical hypnosis and female sexual dysfunction“. Journal of applied health sciences 5, Nr. 1 (15.03.2019): 105–11. http://dx.doi.org/10.24141/1/5/1/10.
Der volle Inhalt der QuelleAnnotation:
Background: Female sexual function comprises variable and multi-layered conditions that incorporate complex interactions of physiological, psychological, and interpersonal components. Despite the progress in understanding the neurobiology of sexual response, the definition of normal sexual response in women remains unresolved. Normal female sexual function differs from individual to individual and depends on the culture, ideology, beliefs, and other factors. Methods: We used a case report, the purpose of which is to justify further investigation into the effectiveness of hypnosis for the treatment of cervical pain during penetration, as well as orgasm disorder. Results: An orgasm was reached by masturbation performed on her by her partner, but without an orgasm by penile-vaginal penetration. The frequency of sexual intercourse has increased (3-4 times/week) in comparison to prior to therapy (once/ 2 months). Orgasm does not occur by self- and by partner masturbation every time, but sporadically; however, more frequently than before therapy. Success has been achieved with the orgasm by penile-vaginal penetration. Conclusions: Hypnotherapy may be a promising co-intervention or intervention per se for both physical and psychological symptoms. The results of hypnotherapy demonstrate that symptoms were significantly alleviated and, consequently, the quality of life improved. Symptoms of pain during sexual intercourse were not eliminated, but the patient had achieved significant control over those symptoms.
4
Cohen, Seth D., Steven Mandel und David B. Samadi. „Assessing Sexual Dysfunction Part 2: Female Sexual Dysfunction“. Guides Newsletter 21, Nr. 3 (01.05.2016): 3–8. http://dx.doi.org/10.1001/amaguidesnewsletters.2016.mayjun01.
Der volle Inhalt der QuelleAnnotation:
Abstract Sexual dysfunction is more common in women (43%) than men (31%), and the evaluating physician must consider the individual's chronological and physiologic age, personal and interpersonal sexual experiences, life events, and relationship issues that may have an effect on female sexual health. The medical history should include focused questions about medical and/or surgical illnesses, use of medications, and urogynecological history. Validated, reliable, standardized questionnaires are useful to identify the presence or absence of various domains of female sexuality such as sexual desire, sexual arousal, orgasm, and/or sexual pain (eg, the Female Sexual Function Index). Serum hormone testing should be dictated by clinical suspicion, and the physician also may assess multiple androgen and estrogen values, as well as pituitary function and levels of thyroid stimulating hormone. Systemic androgens (eg, systemic dehydroepiandrosterone and/or systemic testosterone) may improve mood, energy, stimulation, sensation, arousal, and orgasm in women with sexual health concerns. Combining a biomedical and psychosocial approach to any kind of sexual dysfunction helps to optimize patient outcomes. In the case of hypoactive sexual desire disorder (HSDD), individual or couples-based therapy with a sexual health therapist should be part of the consultation. If the biologic basis of the sexual health concern can be diagnosed by history, physical examination, laboratory testing, and directed imaging studies, then management can be directed to evidence-based management strategies.
5
Khashukoeva, A. Z., M. V. Burdenko, A. V. Overko, T. E. Ryzhova und M. S. Safonina. „Disorders of sexual function in postmenopausal patients“. Meditsinskiy sovet = Medical Council, Nr. 3 (15.04.2021): 106–11. http://dx.doi.org/10.21518/2079-701x-2021-3-106-111.
Der volle Inhalt der QuelleAnnotation:
Introduction. Research in recent years has shown that sexual dysfunction is now common in post-menopausal women and that it has a significant impact on their quality of life.Aim: to identify the major causes of sexual dysfunction in postmenopausal women and their treatment options, by analysing different literature sources.Materials and methods. During the study of this problem, 25 sources of literature, both Russian and foreign, dating from 2007 to 2020 were analysed.Results and discussion. The main etiological aspects of sexual dysfunction in postmenopausal women, such as disorders of sexual desire, sexual pain disorders, orgasmic disorders are considered in this article. The role of physiological processes occurring in a woman’s organism during this age period in the formation of sexual dysfunction is presented, namely, the influence of insufficiency of sex hormones (In particular, estrogens) and genitourinary syndrome on disorders of the sexual sphere.The main methods of treatment are described, including hormone replacement therapy, the use of non-invasive laser technology, and surgical correction of the dysfunction and atrophy of the pelvic floor muscles. Particular attention is paid to the use of the synthetic steroid tibolone and flibanserin, a drug used to treat hypoactive sexual desire disorder, and the data concerning their high efficacy are presented.Conclusions. The predominant manifestation of sexual dysfunction are disorders of sexual desire and sexual pain disorders. Thus it is important to pay attention to this problem and to treat sexual dysfunction by treating its causes.Conclusion. The treatment of sexual dysfunction must address the causes. In many cases, psychotherapy is necessary. MHT has a positive effect on the sexual function of patients. Testosterone therapy is justified in this case, but is rarely used, as it has a number of side effects and contraindications. Synthetic steroids (Tibolone) have shown good results in the treatment of sexual dysfunction.
6
Salehpour, Farzad, Mahsa Khademi, Farzan Vahedifard und Paolo Cassano. „Transcranial Photobiomodulation Therapy for Sexual Dysfunction Associated with Depression or Induced by Antidepressant Medications“. Photonics 9, Nr. 5 (11.05.2022): 330. http://dx.doi.org/10.3390/photonics9050330.
Der volle Inhalt der QuelleAnnotation:
Sexual dysfunction (SD) is frequently encountered in patients suffering from depression. There is a bidirectional relationship between various types of SD and depression, so the presence or treatment of one condition may exacerbate or improve the other condition. The most frequent sexual problem in untreated depressed patients is declining sexual desire, while in treated depressed patients it is difficulties with erection/ejaculation and with orgasm. Numerous classes of neuropsychiatric medications, commonly used in depressed patients—such as antidepressant, antipsychotic, alpha sympathetic, and opioid drugs—may cause SD. Photobiomodulation (PBM) therapy, also called low-level light/laser therapy, is a novel neuromodulation technique for neuropsychiatric conditions, such as depression. Transcranial PBM (tPBM) targets the cellular metabolism—through the mitochondrial respiratory enzyme, cytochrome c oxidase—and has numerous cellular and physiological beneficial effects on the central nervous system. This paper represents a comprehensive review of the application of tPBM to SD, coexisting with depression or induced by antidepressant medications.
7
Mattar, Citra Nurfarah, Yap Seng Chong, Lin Lin Su, Anupriya Aditya Agarwal, PC Wong und Mahesh Choolani. „Care of Women in Menopause: Sexual Function, Dysfunction and Therapeutic Modalities“. Annals of the Academy of Medicine, Singapore 37, Nr. 3 (15.03.2008): 215–23. http://dx.doi.org/10.47102/annals-acadmedsg.v37n3p215.
Der volle Inhalt der QuelleAnnotation:
Introduction: The physiological changes that occur in menopause alter sexual function and affect well-being. Hormonal changes contribute significantly to reduced sexual function in older women and sexual dysfunction may well be amenable to treatment with exogenous hormones or other agents. Materials and Methods: Relevant clinical studies were identified by a computerised literature search. The collated data were presented to fellow gynaecologists for review, analysis of results and discussion in a series of meetings dedicated to finding the best evidence in menopause management. The evidence was assessed and used to prepare guidelines around the management of women who are affected by sexual dysfunction in menopause. Results: Hormone therapy benefits many women who have dyspareunia related to vaginal atrophy, reduced libido and decreased satisfaction, particularly if these symptoms adversely affect their quality of life. Alternative agents such as tibolone and sildenafil citrate can be useful adjuncts. Conclusions: It is increasingly important to recognise postmenopausal sexual dysfunction. Treatment of this syndrome must be individualised to the specific complaints of each woman. Hormones and other agents are relevant treatment options for properly-selected women. Key words: Androgen, Dyspareunia, Oestrogen, Postmenopause, Sex disorders
8
Kim, Young-Joo, und Sung Dae Kim. „Approach to clinical diagnosis and treatment of erectile dysfunction of man“. Journal of Medicine and Life Science 7, Nr. 2 (01.12.2010): 1–6. http://dx.doi.org/10.22730/jmls.2010.7.2.1.
Der volle Inhalt der QuelleAnnotation:
The sexual dysfunction of man is mainly divided into four parts as erectile dysfunction, sexual desire disorder. premature ejaculation and orgasmic disorder. Above of all things, erectile dysfunction is the most important and common disease of these. The past, it is regard to ereclile dysfunction of man is natural event according to aging and little effort to improve or treat about it. But as the molecular biology and pharmacology become more and more advanced, it comes from biological factor and is possible to overcome. The preference of therapeutic option in patients of erectile dysfunction is various but becomes less invasive therapy. The phosphodiesterase type-5 inhibitors (PDE5-ls) sildenafil, vardenafil, tadalafil, urodenafil and mirodenafil are widely used as IirsHine therapy for erecli1e dysfunction (ED). Since the approval of sildenafil in 1998, more than 40 million men worldwide have been successfully treated with PDE5-ls. Pharmacologically, the proven safely and high tolerance of PDE5-ls is an attractive tool to investigate further physiological functions of PDE5, for example the modulation of intracellular cyclic GMP (cGMP) pools. The aim of review is to summarize clinical knowledge and practical approach about erectile dysfunction of man and to share with non-urologist in these information. Therefore, we recommend that even though non-urologist, it is worthy to know of this review.
9
Fedorchenko, Yuliya, und Burhan Fatih Kocyigit. „PERSPECTIVES ON MALE AGING AND THERAPEUTIC IMPLICATIONS“. Central Asian Journal of Medical Hypotheses and Ethics 4, Nr. 3 (29.12.2023): 146–54. http://dx.doi.org/10.47316/cajmhe.2023.4.3.01.
Der volle Inhalt der QuelleAnnotation:
This article provides an in-depth analysis of the molecular and cellular alterations linked to the aging process in males. It elucidates the physiological disruptions that give rise to different diseases and a decrease in functional ability. The inquiry explores the complex correlation between aging, sexual dysfunction, and infertility in males, with a focus on the physiological alterations in spermatogonial stem cells and the impact of oxidative stress on male reproductive capacity. The function of testosterone replacement therapy and its potential advantages in enhancing sexual activity, bone density, and overall health in older males are highlighted. Nevertheless, it is prudent to exercise caution as there is a correlation between testosterone replacement therapy and heightened cardiovascular risk. The article summarizes rehabilitation options for elderly men, specifically focusing on exercise regimens and cardiac rehabilitation, as means to tackle erectile dysfunction and mitigate mortality risks. The advantages of yoga in enhancing mental and physical well-being in males, particularly those grappling with prostate cancer or infertility are mentioned. The significance of adopting a comprehensive and interdisciplinary strategy towards men's health is emphasized, with particular attention given to the contributions of primary care physicians, urologists, and nurses. The significance of customized communication tactics for males and the necessity of periodic examinations for promoting healthier aging are emphasized.
10
Gamidov, S. I., O. Kh Tazhetdinov, A. A. Pavlovichev, A. Iu Popova und R. A. Tkhagapsoeva. „Peculiarities of pathogenesis, diagnostics and treatment of erectile dysfunction in patients presenting with hypogonadism“. Problems of Endocrinology 56, Nr. 5 (15.10.2010): 33–42. http://dx.doi.org/10.14341/probl201056533-42.
Der volle Inhalt der QuelleAnnotation:
Different authors estimate the prevalence of hypogonadism and erectile dysfunction at 1.7% to 35%. The contribution of androgens playing an important role in regulation of erection remains the subject of extensive investigations. To date, experimental and clinical studies have demonstrated that androgen deficiency leads to degeneration and apoptosis of smooth muscle cells followed by fibrosis of cavernous bodies, impaired expression of endothelial and neuronal NO synthase, decreased arterial inflow and increased venous drainage of the cavernous bodies, enhanced sensitivity to mediators of vasoconstriction, impaired NO-mediated relaxation of smooth muscles in response to sexual stimulation, reduced expression of type 5 phosphodiesterase (PDE-5). Moreover, hypogonadism and erectile dysfunction are frequently associated with cardiovascular disorders, diabetes mellitus, metabolic syndrome, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity. The main purpose of hormonal substitution therapy is to maximally normalize the physiological concentration of plasma testosterone and to eliminate clinical manifestations of androgen deficiency. The treatment with testosterone-containing preparations is indicated only for patients with clinical symptoms and laboratory findings suggestive of hypogonadism. The testosterone-based preparations for intramuscular administration currently find wide application for this purpose. Testosterone substitution therapy enhances libido, increases the frequency of morning erection, and improves sexual quality of life at large. It is worthy of note that treatment with these preparations is well tolerated by the patients. Control over hormonal substitution therapy with testosterone preparations implies evaluation of the clinical response and achievement of the target testosterone level in blood plasma. Also. it is necessary to measure PSA, perform digital rectal examination, and determine the hematocrit level prior to the initiation of the treatment, 3 and 6 months after its termination, and every 6 months thereafter. To conclude, androgens are natural stimulators maintaining sexual function in men. Patients with hypogonadism and erectile dysfunction should be managed by combined therapy with androgens and PDE-5 inhibitors.
11
Earle, Sarah, Lindsay O’Dell, Alison Davies und Andy Rixon. „Views and Experiences of Sex, Sexuality and Relationships Following Spinal Cord Injury: A Systematic Review and Narrative Synthesis of the Qualitative Literature“. Sexuality and Disability 38, Nr. 4 (27.08.2020): 567–95. http://dx.doi.org/10.1007/s11195-020-09653-0.
Der volle Inhalt der QuelleAnnotation:
Abstract Research examining the effects of spinal cord injury on sexuality has largely focused on physiological functioning and quantification of dysfunction following injury. This paper reports a systematic review of qualitative research that focused on the views and experiences of people with spinal cord injury on sex and relationships. The review addressed the following research question: What are the views and experiences of people with spinal cord injury of sex, sexuality and relationships following injury? Five databases were relevant and employed in the review: CINAHL (1989–2016 only), PsychInfo, PubMed, Scopus and Web of Science, for research published between 1 January 1980 and 30 November 2019. After removing duplicates, 257 records remained and were screened using a two-stage approach to inclusion and quality appraisal. Following screening, 27 met the criteria for inclusion and are reported in the paper. The review includes studies from fifteen countries across five continents. Two main approaches to data analysis summary and thematic synthesis were undertaken to analyze the qualitative data reported in the papers. The analysis revealed four main themes: sexual identity; significant and generalized others, sexual embodiment; and; sexual rehabilitation and education.
12
Balvočius, Antanas. „Vyrų sutrikusios lytinės funkcijos androgeniniai aspektai“. Lietuvos chirurgija 3, Nr. 4 (01.01.2005): 0. http://dx.doi.org/10.15388/lietchirur.2005.4.2302.
Der volle Inhalt der QuelleAnnotation:
Antanas BalvočiusTarptautinis medicinos centras Union Clinic Vilnius,Tilto g. 1/2, VilniusEl paštas: balvociusa@delfi.lt Įvadas / tikslas Lytinių steroidinių hormonų endokrininiai sutrikimai neigiamai paveikia vyrų lytinę funkciją. Straipsnio tikslas – pateikti pagyvenusių vyrų lytinės disfunkcijos tyrimų ir gydymo rezultatus, apžvelgti mokslinę literatūrą apie endokrininę vyrų lytinės disfunkcijos patofiziologiją, diagnostiką ir gydymą. Ligoniai ir metodai Nuo lytinės disfunkcijos gydyti 64 pagyvenę (50–75 metų, vidutinis amžius 59 metai) vyrai. Erekcijos sutrikimai pagal TEFR-5 skalę svyravo nuo 11 iki 21 balo (vidutiniškai 15,5). Testosterono (T) kraujo serume buvo nuo 15,8 iki 4,6 nmol/L. Mažiau kaip 11 nmol/L rasta 44 vyrams (69%). Pavartoję FDE-5 inhibitorių, erekcijos kokybe buvo nepatenkinti iš 64 net 46 ligoniai, iš jų 35 ligoniams buvo taikytas kombinuotasis gydymas: 250 mg testosterono injekcijos į raumenis kas trys savaitės ir 5-fosfodiesterazės inhibitorius 1 valandą prieš lytinius santykius. Po 3 mėn. lytinės funkcijos pagal TEFR-5 skalę didesnis kaip 21 balas buvo 30 ligonių (85,7%). Rezultatai Hipogonadizmas yra klinikinis ir biocheminis sindromas, pasižymintis nepakankama androgenų koncentracija serume, dėl to gali sumažėti lytinė trauka, pablogėti erekcijos ir gyvenimo kokybė. Jei yra klinikinių indikacijų skirti androgenų terapiją, ja testosterono koncentracija turi būti palaikoma neviršijant fiziologinių ribų. Egzistuoja terapinis sinergizmas, kai esant hipogonadizmui taikomas kombinuotasis gydymas testosteronu ir 5-fosfodiesterazės inhibitoriais. Prieš terapiją ir reguliariai po jos būtina atlikti prostatos digitalinę rektalinę apžiūrą ir nustatyti prostatos specifinius antigenus kraujo serume. Androgenų terapija gali būti trumpalaikė arba ilgalaikė. Pastarajai reikia reguliariai ir dažnai stebėti pacientą, palankų bei šalutinį terapijos atsaką. Išvados Gydant pagyvenusių vyrų lytinę disfunkciją būtina atsižvelgti ir į steroidinių hormonų kiekį kraujo serume bei androgenų terapijos galimybes. Kombinuotąjį gydymą testosteronu ir 5-fosfodiesterazės inhibitoriais reikėtų skirti tiems erekcijos sutrikimų turintiems pacientams, kuriems nepakankamai padeda gydymas vien 5-fosfodiesterazės inhibitoriais. Reikšminiai žodžiai: lytinė disfunkcija; androgenai; andropauzė; testosteronas; prolaktinas dihidrotestosteronas, 5-fosfodiesterazės inhibitoriai, hormonų terapija Androgen aspects of male sexual dysfunction Antanas BalvočiusInternational Medical Center Union Clinic Vilnius,Tilto str. 1/2, Vilnius, LithuaniaE-mail: balvociusa@delfi.lt Background / objective Steroid hormone endocrine disturbances have an adverse impact on sexual function in men. The aim of the article was to present findings of the study on sexual dysfunction in elderly men and results of their treatment together with a review of the literature on pathologic physiology, diagnostics and therapy of male endocrine sexual dysfunction. Patients and methods Sixty four elderly men (aged 50 to 75, mean age 59 years) were treated for sexual dysfunction. The score of erectile disturbances according to International Index of Erectile Function TEFR-5scale ranged from 11 to 21 (mean, 15.5). The blood testosterone (T) level was 15.8 to 4.6 nmol/l. The level lower than 11 nmol/l was found in 44 (69%) patients. Only 46 of 64 patients were not satisfied with the quality of erection after administration of PDE-5 inhibitors. A combined therapy was applied for 35 of 46 patients with a low T level: intramuscular T 250 mg injections three times a week and a FED-5 inhibitor one hour before sexual intercourse. Sexual function of >21 as assessed by TEFR-5 scale was determined for 30 (85.7%) patients after three months. Results Hypogonadism is a clinical and biochemical syndrome characterised by an insufficient serum androgen level, which may result in a decreased libido, lower quality of erection and decreased quality of life. If clinical indications for androgen therapy are present, it shall maintain the level of testosterone within the physiological limits. Therapeutic synergism is observed when a combined treatment including testosterone and phosphodiesterase-5 inhibitors is applied in hypogonadic men. Digital rectal examination of prostate and determination of values of blood serum prostate specific antigens are indispensable before the initiation of therapy and must be performed regularly afterwards. Androgen therapy may be short-term or long-term, and requires regular and frequent monitoring and observation for favourable and side response to the treatment. Conclusions The level of blood serum steroid hormones should be taken into account and the possibilities for androgen therapy considered in the therapy of sexual dysfunctions in elderly men. A combined treatment of erectile disorders with testosterone and phosphodiesterease-5 inhibitors should be administered to the patients in whom the treatment with phosphodiesterease-5 inhibitors alone is not helpful. Keywords: sexual dysfunction, androgens, andropause, testosterone, prolactin, dihydrotestosterone, phosphodiesterease-5 inhibitors, hormone therapy
13
Bezkor, Mary F., und Angelo Canedo. „Physiological and psychological factors influencing sexual dysfunction in Multiple Sclerosis: Part II emotionality and sexuality in persons with Multiple Sclerosis“. Sexuality and Disability 8, Nr. 3 (September 1987): 147–51. http://dx.doi.org/10.1007/bf01376985.
Der volle Inhalt der Quelle
14
Arlt, Wiebke. „Androgen therapy in women“. European Journal of Endocrinology 154, Nr. 1 (Januar 2006): 1–11. http://dx.doi.org/10.1530/eje.1.02062.
Der volle Inhalt der QuelleAnnotation:
Androgens in women either derive from direct ovarian production or from peripheral conversion of the adrenal sex steroid precursor, dehydroepiandrosterone, towards active androgens. Therefore, loss of adrenal or ovarian function, caused by Addison’s disease or consequent to bilateral oophorectomy, results in severe androgen deficiency, clinically often associated with a loss of libido and energy. Importantly, physiological menopause does not necessarily lead to androgen deficiency, as androgen synthesis in the ovaries may persist despite the decline in estrogen production. However, the definition of female androgen deficiency, as recently provided by the Princeton consensus statement, is not precise enough and may lead to over-diagnosis due to the high prevalence of its diagnostic criteria: androgen levels below or within the lower quartile of the normal range and concurrent sexual dysfunction. Importantly, physiological menopause is not necessarily associated with androgen deficiency and therefore does not routinely require androgen therapy. Current replacement options include transdermal testosterone administration or dehydroepiandrosterone treatment, both of which have been shown to result in significant improvements, in particular in libido and mood, while effects on body composition and muscular function are not well documented. It is important to keep in mind that the number of randomized controlled trials is still limited and that currently none of the available preparations is officially approved for use in women. Currently, androgen replacement should be reserved for women with severe androgen deficiency due to an established cause and matching clinical signs and symptoms.
15
De Sousa Cavalcante Costa, Marciene, Adriana Gomes Nogueira Ferreira, Ana Cristina Pereira de Jesus Costa und Camila Teixeira Moreira Vasconcelos. „EFICÁCIA DO TREINAMENTO DOS MÚSCULOS DO ASSOALHO PÉLVICO NO TRATAMENTO DAS DISFUNÇÕES SEXUAIS FEMININAS: REVISÃO NARRATIVA“. Revista Enfermagem Atual In Derme 97, Nr. 2 (24.04.2023): e023061. http://dx.doi.org/10.31011/reaid-2023-v.97-n.2-art.1422.
Der volle Inhalt der QuelleAnnotation:
Objetivo: O objetivo do estudo foi descrever sobre o efeito dos protocolos de treinamento dos músculos do assoalho pélvico utilizados para o tratamento das disfunções sexuais femininas. Métodos: A busca eletrônica foi realizada em dezembro de 2021, nas bases de dados MEDLINE/Pubmed e SciELO (Scientific Electronic Library Online). Os descritores controlados selecionados no MeSH foram “exercise therapy” e “sexual dysfunction, physiological”. Os descritores não controlados delimitados foram “pelvic floor muscle training” e “female sexual dysfunction”. Foram incluídos estudos que tratavam do treinamento dos músculos do assoalho pélvico como intervenção fisioterapêutica para o tratamento das disfunções sexuais femininas nos idiomas inglês e português publicados até o ano de 2021. Resultados: Foram excluídos artigos de revisão, teses, dissertações e artigos que abordavam sobre patologias neurológicas. Os 12 artigos incluídos analisaram protocolos de treinamento dos músculos do assoalho pélvico supervisionados e em domicilio e quanto aos protocolos de intervenções estes apresentam-se associados com outras intervenções como eletroestimulação, liberação miofascial, uso de lubrificantes e hidratantes vaginais. Conclusões: o treinamento dos músculos do assoalho pélvico realizados tanto de forma supervisionada como em domicilio se mostraram viáveis e efetivos na melhora da função sexual de mulheres saudáveis além de mulheres com disfunções do assoalho pélvico.
16
Rosenberg, Shoshana, Rulla M. Tamimi, Shari I. Gelber, Kathryn Jean Ruddy, Sandra Kereakoglow, Virginia F. Borges, Steven E. Come, Lidia Schapira, Eric Winer und Ann H. Partridge. „Sexual functioning in young women with breast cancer.“ Journal of Clinical Oncology 30, Nr. 15_suppl (20.05.2012): 9100. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9100.
Der volle Inhalt der QuelleAnnotation:
9100 Background: Sexual dysfunction is a known complication of adjuvant therapy for breast cancer and an important determinant of quality of life. Little is known about the frequency and magnitude of this problem among very young women with breast cancer during the year following diagnosis. Methods: 298 sexually-active women enrolled in an ongoing multi-center cohort study with Stage 0-III breast cancer at or before age 40 were included in this analysis. Treatment data was self-reported on a survey mailed to participants at enrollment. Sexual functioning was assessed using the sexual interest and dysfunction subscales from the Cancer Rehabilitation Evaluation System (CARES). Scores range from 0-4, with higher scores indicative of poorer function. The survey included a measure of anxiety and depression (Hospital Anxiety and Depression Scale), of body image (CARES) and of physical and menopausal symptoms (Breast Cancer Prevention Trial Symptom Checklist). Mean differences in CARES scores between treatment groups (chemotherapy vs. none; hormone therapy vs. none; lumpectomy vs. mastectomy vs. mastectomy + reconstruction vs. no surgery; radiation vs. none) were compared using T-tests and ANOVA. Multiple regression models were fit to assess symptoms thought to be mediators of the treatment-sexual functioning association. Results: Mean age at diagnosis was 36 (range: 22-40) years and mean time from diagnosis to survey completion was 5 months (range: 1-16). Mean CARES sexual interest and dysfunction scores were higher in women who received chemotherapy compared to those who did not (p<0.0001). In the multivariate analysis, chemotherapy was no longer associated with decreased sexual interest or function. Anxiety, depression, musculoskeletal pain, and poorer body image were predictive of both decreased sexual interest and function. Vaginal pain symptoms were associated with greater dysfunction, while unhappiness with appearance was associated with decreased interest. Conclusions: Young women who receive chemotherapy are at risk for problems related to sexual functioning early in the survivorship period. This effect appears to be mediated through several physiologic and psychologic mechanisms, underscoring the need for interventions that target both.
17
Falavigna, Asdrubal, Guilherme Finger, Olívia Egger de Souza und Fabio Firmbach Pasqualotto. „Spinal cord injury and male infertility: a review“. Coluna/Columna 11, Nr. 4 (Dezember 2012): 322–25. http://dx.doi.org/10.1590/s1808-18512012000400015.
Der volle Inhalt der QuelleAnnotation:
Spinal cord injuries remain an important factor of morbimortality in current society, involving mainly males from adolescence to adulthood. Among the sequelae caused by spinal cord injuries, the impairment of the sexual system is highly relevant since it affects the quality of sexual life and paternity. Infertility is secondary to multiple events such as erectile dysfunction, anejaculation, seminal biochemical modification and morphology of spermatozoa. Current therapies for the infertile spinal cord injured patient focus on the ejaculation stimulus followed by intrauterine insemination, leaving seminal low quality as the major factor of infertility in these patients. In this scenario, therapy with hyperbaric oxygenation, which is still being studied, represents an alternative treatment since it focuses on the central nervous system injured by the trauma and the testicular tissue in order to decrease spinal damage and to preserve the physiological regulation of the urogenital system as a form of avoiding infertility.
18
Mykoniatis, Ioannis, Koenraad Van Renterghem und Ioannis Sokolakis. „How can we Preserve Sexual Function after Ablative Surgery for Benign Prostatic Hyperplasia?“ Current Drug Targets 22, Nr. 1 (31.12.2020): 4–13. http://dx.doi.org/10.2174/1389450121666200925143916.
Der volle Inhalt der QuelleAnnotation:
: Our aim is to provide a narrative review regarding the prevalence, the associated pathophysiologic pathways and the potential management methods of sexual dysfunction related to ablative surgical techniques for Benign Prostatic Enlargement (BPE). Men suffering from BPE are at high risk of sexual dysfunction due to the disease itself, comorbidities, and pharmacological/surgical treatments. Transurethral resection of the prostate, as the gold standard treatment option for BPE has historically been associated with relatively high rates of postoperative sexual dysfunction problems, mainly retrograde ejaculation but also erectile dysfunction. Ablative surgical techniques, including photoselective vaporization of the prostate (PVP), transurethral needle ablation (TUNA), Transurethral Microwave Therapy (TUMT), Convective Water Vapor Energy Ablation (Rezum®) and Aquablation® have been proposed as treatment methods able to reduce treatment-related complications for BPE patients, including adverse effects on erectile and ejaculatory function, without compromising the efficacy rates for BPE. The neurovascular bundles can be damaged during TURP due to posterolateral capsular perforation. Ablative techniques and especially PVP theoretically seems to skip this hazard as the distance created from the necrotic area to the capsule is generally larger compared to the distance induced after TURP . However, indirect thermal injury of erectile nerves, which could be induced also by the majority of available ablative techniques could potentially lead to ED. Two special technical characteristics (physiological saline use for tissue ablation and real time penetration depth control) of Aquablation® could be proved beneficial with regard to the effect of the method on erectile function. In general ablative techniques seems to have minor impact on sexual function. However, low methodological quality characterize the most of the studies included in this review mainly due to the impossibility, in many cases, to perform a blind randomization. Also in many studies did not have erectile and ejaculatory function as primary outcomes limiting that way their statistical power to identify significant variations. Management of sexual dysfunction problems arising from ablative surgeries for BPE treatment could be divided in two levels. Firstly, intraoperatively the avoidance of manipulation of crucial structures regarding ejaculatory (bladder neck or ejaculatory ducts) and erectile function (neurovascular bundles) could possibly decrease the negative effect of these procedures on sexual function. Thus, in this direction, modifications of classic ablative techniques have been proposed resulting in encouraging outcomes regarding postoperative sexual function. Secondly, if EjD and/or ED are established the already known treatment choices should be chosen in order sexual function rehabilitation to be achieved. Thus, regarding ED: PDE5i daily or on demand remain the gold standard first line treatment choice followed by intracaver-nosal alprostadil injections in cases of failure, while penile prosthesis implantation must be kept as final definitive solution when all the other methods have failed. Regarding ejaculation disorders (retrograde ejaculation or anejaculation): medical therapy with a-agonists (pseudoephedrine), sperm retrieval from the urine, bladder neck reconstruction, prostatic massage, electroejaculation, penile vibratory stimulation and surgical sperm retrieval are the available treatment options. Further, high quality studies are required to investigate potential side effects of BPE surgery on sexual function and efficient treatment methods to manage them.
19
Aarshageetha, P., P. R. Rani Janci und N. Devi Tharani. „Role of Alternate Therapies to Improve the Quality of Life in Menopausal Women: A Systematic Review“. Journal of Mid-life Health 14, Nr. 3 (2023): 153–58. http://dx.doi.org/10.4103/jmh.jmh_222_22.
Der volle Inhalt der QuelleAnnotation:
Middle aged women in majority undergoing menopausal symptoms are unaware of the physiological changes happening in their body, necessary lifestyle changes and alternate therapies to overcome the symptoms. All major electronic sources of relevant information were systematically searched and collected data were pooled under specific subheadings. From the reviewed papers, the awareness on symptoms and related complications of menopause in the middle aged women were consolidated. Studies helped to identify alternative therapies replacing or in parallel with the Hormone Replacement Therapy to overcome the menopausal symptoms. Reduced oestrogen and progesterone level causes physiological, psychological, and genitourinary symptoms. Prolonged consequences cause libido, osteoporosis, and cardio vascular diseases. Hypo-estrogenic status is well managed with alternative therapies including dietary intervention, acupuncture, aromatherapy, exercise, and yoga. Dietary interventions involving foods like Fennel, Soy, Black Cohash, St. John Wort, Red Clover and Date Pollen were found to be managing vasomotor symptoms and sexual dysfunction. Non-Hormonal and Non-Pharmacological impact behind acupuncture treatment was well accepted. Various studies proved inhaling and massaging with Lavender, Neroli oil, Fennel, Rose, and Geranium essential oils balance cortisol hormone and reduce stress and anxiety. Impact of yoga therapy on neurohormonal pathways reduce both psychological and physiological symptoms. Reviews summarizes various symptoms and complications during menopausal transition and alternate ways of better management with dietary intervention, yoga, exercise, aromatherapy, and acupuncture to improve the quality of menopausal women’s life.
20
Barbosa, João Arthur Brunhara Alves, und José Cury. „Androgen replacement therapy in men: current evidence and controversy“. Revista de Medicina 97, Nr. 3 (18.07.2018): 295–300. http://dx.doi.org/10.11606/issn.1679-9836.v97i3p295-300.
Der volle Inhalt der QuelleAnnotation:
The decline in Testosterone (T) levels in the ageing male - known as andropause or late-onset hypogonadism - may be responsible for several aspects of quality of life decline in older men: erectile dysfunction, impaired libido, decreased strength and energy, sarcopenia, osteopenia, fatigue and even depression in some cases. Many of these signs and symptoms represent the same alterations that are usually attributed to the process of ageing. When some individual presents with such symptoms, hypogonadism should be suspected, and serum T level should be evaluated. Men who are symptomatic and present low levels of serum Testosterone (generally below 300 ng/ml) are candidates for T replacement therapy. Current evidence shows that, when correctly selected, patients receiving T replacement may benefit from improvement in libido, erectile function, overall and sexual related quality of life, bone density and muscle mass. Conversely, patients with physiological circulating levels of T who receive hormone, aiming at supraphysiologic levels, may face severe side effects, including testicular atrophy and behavioral changes. Of note, T replacement, regardless of age and pre-therapy levels, leads to fertility impairment which can be transient or persistent. Direct testosterone replacement should not be indicated in men who wish to conceive children, although other options are available. The effect of Testosterone replacement on prostate cancer and on cardiovascular risk is still controversial; hypogonadal men known to have prostate cancer or high cardiovascular risk should be examined individually to have their risks stratified and mitigated.
21
Perrotta, Giulio. „The Concept of “Hypersexuality” in the Boundary between Physiological and Pathological Sexuality“. International Journal of Environmental Research and Public Health 20, Nr. 10 (17.05.2023): 5844. http://dx.doi.org/10.3390/ijerph20105844.
Der volle Inhalt der QuelleAnnotation:
Introduction: The concept of hypersexuality belongs to modern parlance, according to a predominantly clinical meaning, and is understood as a psychological and behavioural alteration as a result of which sexually motivated stimuli are sought in inappropriate ways and often experienced in a way that is not completely satisfactory. Methods: Literature up to February 2023 was reviewed, with 25 searches selected. Results: Forty-two articles were included in the review. Conclusion: Hypersexuality is a potentially clinically relevant condition consisting of one or more dysfunctional and pathological behaviours of one’s sexual sphere and graded according to the severity of impairment of subjective acting out; for this reason, the Perrotta Hypersexuality Global Spectrum of Gradation (PH-GSS) is suggested, which distinguishes high-functioning forms (pro-active and dynamic hypersexuality) from those of attenuated and corrupted functioning (dysfunctional and pathological hypersexuality of grades I and II). Future research is hoped to address the practical needs of this condition, such as the exact etiopathology, the role of oxytocin in dopaminergic hypotheses (and its ability to attenuate the symptomatology suffered by the patient in terms of manic drive), the best structural and functional personality framing of the subject, and the appropriate therapy to pursue.
22
Nale, Dj, P. Nikic, I. Vukovic und D. Djordjevic. „Surgical or conservative treatment of penile fracture“. Acta chirurgica Iugoslavica 55, Nr. 1 (2008): 107–14. http://dx.doi.org/10.2298/aci0801107n.
Der volle Inhalt der QuelleAnnotation:
Introduction: Penile fracture presents with rupture of corpora cavernosa. It is not rare but is remarkable. Treatment options are controversial. Aim: To establish the incidence, what are early and late complications in patients treated surgically or with conservative treatment options (prospective/retrospective and randomized analysis). To find out what therapy verified as superior. Material and method: The total of 32 patients with typical acute penile fracture were analyzed. The patients were between 20 and 56 years of age (Mean age 40+7.25 SD). A total of 11 patients that presented up to 48h after the rupture of tunica albuginea (34.37%) were operated, while 9 patients (28.13%) were conservatively treated. 12 patients (37.5%) reported to andrology consulting room due to penile fibrous alterations and/or erectile dysfunction 6 to 14 months after the anamnesticaly established, typical penile fracture ("primary latent penile fracture"). Both groups of patients were strictly clinically followed 3, 6, 9 and 12 months after the penile fracture. Eventual development of late complications (erectile dysfunction ED, penile curvature, induratio, caverno-urethral fistula and urethral stenosis) was also recorded. Etiology of ED was investigated: anamnesticaly, by hormone and laboratory analysis, using penodynamic test (PGE1), Duplex Doppler echosonography, and dynamic cavernosography. Results: In the operated group of patients, (11 pts, 34.37%) preserved erectile capacity was recorded and no penile deformity or plaque lesions on the site of suture, after the patients were recommended to have 4 weeks of sexual abstinence. The rupture of tunica albuginea was always transversal in relation to penile axis i.e. in relation to axial force against which the penis acts during the intercourse. The rupture is always on the basis or mid penile portion . Out of 21 (65.63%) conservatively treated patients in 13 (61.9%) plaque lesions (longitudinal diameter 2 cm) was recorded, while sexual dysfunction was established in 13 patients (12 with ED and 1 patient with incapability for vaginal penetration). Evaluation of post therapeutical complications in relation to type of treatment, significantly higher frequency was recorded in the group of conservatively treated patients (p<0.01). Penile veno-oclusive dysfunction was registrated as significantly most frequent cause of ED (in 10 - 76.92% out of 13 patients). All patients with ED had palpable fibrous lesion similar to Peyrone?s plaque, while the degree of penile deviation correlated to the size of plaque lesion. Conclusion: The late complications of penile fracture were significantly more frequently recorded in the group of conservative treated patients (p< 0.01) which proves that this lesion presents as urgent urological entity. The penile rupture is always transversal, and most probable place of rupture is physiological penile curve since this is the site of weakened structural integrity.
23
Tsepkolenko, Oleksandra V. „Olfactory dysfunction: prevalence, diagnosis and treatment“. OTORHINOLARYNGOLOGY No6(4) 2021, No6(4) 2021 (30.12.2021): 74–86. http://dx.doi.org/10.37219/2528-8253-2021-6-74.
Der volle Inhalt der QuelleAnnotation:
Topicality: Odors affect the vital body functions, the general psychophysiological state. The sense of smell plays an important role in regulating human behavior. For example, the olfactory impulse reaches the brain faster than the impulse of pain, and therefore very effectively regulates us, regardless of awareness. Odors can change the work of various body systems: they affect the rhythm of our breathing, the excitability of muscles, the work of the brain and the entire nervous system. The sense of smell affects the limbic system, the part of the brain that controls hunger, feelings of aggression, sexual emotions and other "animal" feelings of a person. OD violates the informational and controlling roles of odorous substances (attractants, repellents, pheromones), therefore disorganizing the performance of nutritional, sexual, protective, orientation functions. For people of some specialties (taster, perfumer, cook), the decrease in the sense of smell can mean job loss and social maladaptation. Complaints about problems with taste perception more often reflect violations of the sense of smell, since the taste of a number of foods (chocolate, coffee, vanilla, strawberries, etc.) in reality depends on the stimulation of the sense of smell by volatile components that enter the nasopharynx when swallowing. Aim: To offer an otorhinolaryngologist guidance in the information stream regarding the problem of olfactory dysfunction, its prevalence, diagnosis and treatment. Materials and methods: The Sniffin’ Sticks test (CST) has been certified in the EU since 1995, and is used in Germany, Austria, Switzerland, and Italy. Odors are offered in the form of markers, in which the odorous substance takes the place of the coloring one. There is a version with 16 odors from the extended test [extendid] or with 12 odors [screening]. The test is well validated, can, unlike CCSIT, be used repeatedly, the shelf life is 0.5-1 year, depending on the intensity of application. The test can be used by patients independently. The study consists of 3 stages: threshold test (THR) – determination of the minimum odor concentration that the patient feels; discrimination test (D) is aimed at identifying the patient's ability to distinguish odors; identification test (I) for odor recognition. "University of Pennsylvania Smell Identification Test" (UPSIT) – the test is used exclusively to identify 40 odors (some of them are little known outside of North America). Odorous substances are microcapsulated on paper in the form of a rectangle and are released as a result of friction when held over it with a simple pencil. The patient is given 4 possible answers. Normally, a healthy man correctly identifies 34-40 odors, a healthy woman – 35-40. If the subject scores 18 or less, it is considered that he has a complete loss of sense of smell. The test system is a single-use and expensive. Digital volumetric tomography (CT). The visualization of the olfactory cleft, the upper nasal concha, and the configuration of the olfactory groove (OJ) turned out to be informative. Results and discussions: The review discusses the unique properties of OE and the potential use of olfactory epithelial grafts to restore olfactory function. Permanent population of multipotent stem cells proliferating throughout the life of the organism is located in the mammal OE. The cells formed during division go through several stages of differentiation and replace the dying olfactory receptor neurons. Neural stem cells were isolated from the olfactory region of the mucous membrane of humans, rats and mice. It is this population of neural stem cells that is being investigated as an autologous material for transplantation and the future use of olfactory transplants as a potential method of restoring the sense of smell. OE survives when transplanted to various areas of the brain, can be grafted directly to OL. Conclusions: A new direction in the treatment of OD is associated with cell therapy technologies, for example, using platelet-rich plasma (PRP), plasma in which the concentration of platelets is several times higher than normal. The term PRP is legitimate at a concentration of 700 thousand to 1 million platelets in 1 ml of plasma (the physiological plasma concentration of platelets is (180-360) x109 per liter). PRP is used to accelerate tissue regeneration, reduce scarring, stimulate angiogenesis, as well as a local antiseptic. The spectrum of pharmacological action of PRP is determined by growth factors: platelet growth factor (PDGF), transforming growth factor (TGF-β), vascular endothelial growth factor (VEGF), epithelial growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF). The active secretion of these growth factors by platelets begins within 10 minutes after activation (activation can be stimulated by almost any environmental disturbance, up to a simple mechanical stress), while more than 95% of the previously synthesized growth factors are secreted within 1 hour.
24
Vasileva, Zdravka. „Melatonin and Epilepsy“. Folia Medica 63, Nr. 6 (31.12.2021): 827–33. http://dx.doi.org/10.3897/folmed.63.e58637.
Der volle Inhalt der QuelleAnnotation:
Epilepsy is a chronic neurological disease with recurrent seizures. Its incidence, the social and psychological aspects of epilepsy-associated stigmatization in society, the medical risk of severe seizures, and the challenges in treatment confirm its medical and social significance. The pathogenesis of the diseases is associated with abnormal activity of a population of neurons due to various mechanisms, the most frequent being oxidative stress, glutamate excitotoxicity, and mitochondrial dysfunction. In the last 3-4 decades, the possible connection between epilepsy and melatonin – a neurohormone secreted by the pineal gland – has been sought and studied. Various physiological functions of melatonin in humans have been proven – regulation of circadian rhythms (diurnal, seasonal), sleep and wakefulness, participation in the processes of thermoregulation, tumour growth and aging, sexual activity and reproductive functions. It also has immunomodulatory, cytoprotective and antioxidant activity. The results from the studies with experimental models with animals conducted so far in search of a correlation between melatonin and epileptogenesis are mainly in support of the hypothesis of its anticonvulsant effect. The studies with humans are diverse in design, with a smaller number of participants, and the results are not always in explicit support of this hypothesis. The correlation between melatonin concentration and the course of the disease in patients with epilepsy has been discussed. The possibility of adding melatonin to anti-epileptic therapy has also been studied recently.
25
Skliarov, Pavlo, Serhiy Fedorenko, Svitlana Naumenko, Vsevolod Koshevoy und Kateryna Pelyh. „The Development of Phyto- and Tissue Origin Medicines for Veterinary Reproductive Issues“. Scientific Horizons 24, Nr. 8 (29.12.2021): 15–25. http://dx.doi.org/10.48077/scihor.24(8).2021.15-25.
Der volle Inhalt der QuelleAnnotation:
Modern conditions of practical veterinary medicine require the use of effective and safe drugs. Along with the already known and common medicines, the search for new drugs which are harmless for the body and have the physiological direction of action is still required. In recent years, the attention to the use of phyto- and tissue-derived drugs increased. However, the problem of their use is insufficiently studied – many aspects of their clinical use require further development, expansion of the spectrum of used medicinal plants, study, and implementation into veterinary practice. Therefore, the purpose of this work was to develop a comprehensive vitamin-hormone drugs based on phyto- and tissue medicines for the treatment and prevention of reproductive abnormalities in animals. Based on the information on the etiopathogenesis of disorders of reproductive function indicators: homeostasis, reducing of the concentration of hormones (estrogen or progesterone), changes in the morphofunctional state of endocrine (pituitary, thyroid, and adrenal gland) and reproductive (ovaries) organs, the application of vitamin-hormone drugs in veterinary medicine is scientifically sound. Drugs in terms of pathogenetic therapy can optimise homeostasis, hormone concentrations, stimulate rehabilitation processes in the regulatory organs of reproductive function (pituitary, adrenal, and thyroid) and reproductive organs (ovaries), which, in turn, contributes to the normalisation of follicles which are a prerequisite for the full reproductive capacity of females. Vitamin-hormonal medicines of herbal and tissue origin were developed, with high efficiency for the treatment and prevention of reproductive pathologies of various species of animals, providing the stimulation of reproductive function (estrus signs) for therapy of females with gonadopathies (“Carafest”, “Caplaestrol” and “Caplagonìn”) and males (display of sexual reflexes and sperm quality) for reproductive activity dysfunction (“Carafand”), increase in the viability of the newborn (increasing the number of lambs and goatlings with satisfactory clinical condition with a high-growth potential, reduce in their morbidity and lethality), preventing the incidence of ìntra- and postnatal (labor hypofunction, diseases of post-labor period) pathology (“Carafest”, and “Caplaestrol”)
26
Gopchuk, О. М., und Р. V. Samaniv. „Problems of the thin endometrium. New possibilities of FDE-5 inhibitors“. Reproductive health of woman, Nr. 2 (29.04.2022): 47–52. http://dx.doi.org/10.30841/2708-8731.2.2022.261807.
Der volle Inhalt der QuelleAnnotation:
The article is devoted to a review of the literature about the thin endometrium and its correction today. The problem of thin endometrium is very significant in cases of unsuccessful embryo implantation. There is no generally accepted approach to the definition of “thin endometrium” and ways of its correction in the literature. Phosphodiesterase type 5 (PDE5) inhibitors are considered to play a role in increasing endometrial thickness and improving pregnancy outcomes. Their action consists of various mechanisms, in particular, such as the induction of vasodilating effect through the effect on signaling to vascular smooth muscle, through the regulation of cell proliferation and induction of angiogenesis by increasing the expression of tumor suppressor factor (p53) and vascular endothelial growth factor A, the inhibition of inflammation by reducing the regulation of proinflammatory cytokines. Although PDE5 inhibitors increase the endometrial thickness through the various mechanisms, especially in women with thin endometrium, it does not necessarily mean that they have a positive effect in all clinical situations. Meanwhile, the successful outcome may be affected by the time of use of the drug, the type of infertility treatment, the main diseases such as pelvic disorders and inflammation. Therefore, there are ambiguous issues that need further research in this problem. Oral PDE5 inhibitors are also used as first-line therapy for the treatment of erectile dysfunction (ED), they have proven effectiveness, tolerability, action and couple satisfaction. Avanafil is the only selective inhibitor of the PDE5 isoenzyme with a low frequency of side effects compared to other drugs in this group. The high tolerability of these drugs has made them an attractive tool for the study of further physiological functions outside the ED with benefits for many non-sexual consequences.
27
Luo, Lanfang, Fangfang Wang, Ling Wang, Jing Zhang, Xiaoyu Liu und Weifen Wang. „Clinical Efficacy and Psychological Impact of Omaha-Based Continuing Care for Prostate Cancer Patients“. Computational and Mathematical Methods in Medicine 2022 (05.07.2022): 1–7. http://dx.doi.org/10.1155/2022/8735363.
Der volle Inhalt der QuelleAnnotation:
Prostate cancer is a common malignancy elderly male urogenital system, because of the special disease position, and postoperative complications such as urinary retention, urinary incontinence, and sexual dysfunction, if not treated, can increase the patients’ physical pain, anxiety, and other psychological burden; endocrine therapy after surgery can affect self-image and quality of life of patients. Omaha system was originally used for community health nurses, which contains three main contents: problem classification, nursing intervention, and outcome evaluation. The problem classification dimension includes four dimensions: environment, physiology, social psychology, and health-related behavior. The nursing intervention dimension is composed of 75 intervention objectives and four behavior types. Omaha system is a nursing intervention model based on individual psychological, physiological, educational level, and family and social background. The model has good clinical application effect. This study aimed to explore the continuous nursing intervention effect in the nursing of patients with prostate cancer and its psychological impact. A total of 96 prostate patients with cancer who were admitted to Taizhou First People’s Hospital from November 2019 to May 2021 were divided into Omaha system care group and routine care group with 48 cases each by random number table method. The routine care group received routine care and discharge guidance, and the Omaha system care group on the basis of the routine care group; continuation care based on the Omaha system was implemented. The differences in mental state, life quality score, serum prostate specific antigen (PSA) level, average urine flow rate, and self-care ability score were compared between the routine care and Omaha system care group. The results showed that Omaha-based continuation care for prostate cancer is beneficial to reduce bad mood, improve patients’ life quality score and self-care ability, and provide certain reference for clinical care of prostate cancer patients.
28
Suba, Zsuzsanna, und Miklós Kásler. „Interactions of insulin and estrogen in the regulation of cell proliferation and carcinogenesis“. Orvosi Hetilap 153, Nr. 4 (Januar 2012): 125–36. http://dx.doi.org/10.1556/oh.2012.29287.
Der volle Inhalt der QuelleAnnotation:
Equilibrium of sexual steroids and metabolic processes has close correlations. Insulin is a potent regulator of human sexual steroid hormone production and modulates their signals at receptor level. Insulin resistance and excessive insulin production provoke hyperandrogenism and estrogen deficiency in women resulting not only in anovulatory dysfunction but also a high risk for cardiovascular diseases and cancer. Physiologic functions of all female organs have higher estrogen demand as compared with men. In healthy women estrogen predominance against androgens is a favor in their reproductive period, which means a strong defense against insulin resistance and its complications. However, in postmenopausal cases the increasing prevalence of insulin resistance and type-2 diabetes associated with estrogen deficiency and androgen excess, result in a gender specific higher risk for precancerous lesions and cancer as compared with men. Estrogen has beneficial effect on the energy metabolism, glucose homeostasis and on the lipid metabolism of liver and of peripheral tissues as well. A moderate or severe decrease in serum estrogen level enhances the prevalence of insulin resistant states. In premenopausal women long or irregular menstrual cycles are predictors for the risk of insulin resistance and type-2 diabetes. Moreover, in postmenopausal estrogen deficient cases elevated fasting glucose, increased body weight and abdominal fat deposition are often observed progressively with age in correlation with an impaired glucose tolerance. In the rare cases of estrogen deficient men severe type-2 diabetes seems to be a characteristic complication. Upon becoming familiar with the cancer risk of insulin resistance and estrogen deficiency, there would be plenty of possibilities for primary cancer prevention. In patients with cancer the treatment of hormonal and metabolic disturbances may become effective adjuvant therapy. Orv. Hetil., 2012, 153, 125–136.
29
Laird, Lyle K. „Sexual Dysfunction on Fluvoxamine Therapy“. Journal of Clinical Psychiatry 61, Nr. 1 (15.01.2000): 62. http://dx.doi.org/10.4088/jcp.v61n0114c.
Der volle Inhalt der Quelle
30
Waldinger, Marcel D., und Berend Olivier. „Sexual Dysfunction and Fluvoxamine Therapy“. Journal of Clinical Psychiatry 62, Nr. 2 (15.02.2001): 126–27. http://dx.doi.org/10.4088/jcp.v62n0210b.
Der volle Inhalt der Quelle
31
Hopwood, C. „Surrogate therapy for sexual dysfunction“. Medical Journal of Australia 156, Nr. 2 (Januar 1990): 143. http://dx.doi.org/10.5694/j.1326-5377.1992.tb126456.x.
Der volle Inhalt der Quelle
32
Crowe, Michael. „Couple Therapy and Sexual Dysfunction“. International Review of Psychiatry 7, Nr. 2 (Januar 1995): 195–204. http://dx.doi.org/10.3109/09540269509028327.
Der volle Inhalt der Quelle
33
Szoeke, C., und L. Dennerstein. „Therapy of Female Sexual Dysfunction“. Zentralblatt für Gynäkologie 124, Nr. 2 (2002): 84–95. http://dx.doi.org/10.1055/s-2002-24238.
Der volle Inhalt der Quelle
34
Davis, Susan R., und Esme A. Nijland. „Pharmacological Therapy for Female Sexual Dysfunction“. Drugs 68, Nr. 3 (2008): 259–64. http://dx.doi.org/10.2165/00003495-200868030-00001.
Der volle Inhalt der Quelle
35
Pereira, Valeska, Oscar Arias-Carrión, Sergio Machado, Antonio Nardi und Adriana Silva. „Sex therapy for female sexual dysfunction“. International Archives of Medicine 6, Nr. 1 (2013): 37. http://dx.doi.org/10.1186/1755-7682-6-37.
Der volle Inhalt der Quelle
36
Anson, Martin. „Non-Couple Therapy for Sexual Dysfunction“. International Review of Psychiatry 7, Nr. 2 (Januar 1995): 205–16. http://dx.doi.org/10.3109/09540269509028328.
Der volle Inhalt der Quelle
37
Segraves, Robert Taylor. „Sexual Dysfunction Associated with Antidepressant Therapy“. Urologic Clinics of North America 34, Nr. 4 (November 2007): 575–79. http://dx.doi.org/10.1016/j.ucl.2007.08.003.
Der volle Inhalt der Quelle
38
Mark, Alice, und Jan Shifren. „Medical therapy for female sexual dysfunction“. Primary Care Update for OB/GYNS 10, Nr. 1 (Januar 2003): 40–43. http://dx.doi.org/10.1016/s1068-607x(02)00144-0.
Der volle Inhalt der Quelle
39
Kim, Edward D. „Hormonal therapy for male sexual dysfunction“. Fertility and Sterility 97, Nr. 5 (Mai 2012): 1248. http://dx.doi.org/10.1016/j.fertnstert.2012.03.026.
Der volle Inhalt der Quelle
40
Diemont, Willem L., Peter A. Vruggink, Eric J. H. Meuleman, Wim H. Doesburg, Wim A. J. G. Lemmens und Jo H. M. Berden. „Sexual dysfunction after renal replacement therapy“. American Journal of Kidney Diseases 35, Nr. 5 (Mai 2000): 845–51. http://dx.doi.org/10.1016/s0272-6386(00)70254-x.
Der volle Inhalt der Quelle
41
Bradway, Christine, und Joseph Boullata. „Pharmacologic therapy for female sexual dysfunction“. Nurse Practitioner 39, Nr. 1 (Januar 2014): 16–27. http://dx.doi.org/10.1097/01.npr.0000440641.32261.7c.
Der volle Inhalt der Quelle
42
&NA;. „Pharmacologic therapy for female sexual dysfunction“. Nurse Practitioner 39, Nr. 1 (Januar 2014): 27–28. http://dx.doi.org/10.1097/01.npr.0000441344.85393.1e.
Der volle Inhalt der Quelle
43
Khera, Mohit. „Testosterone Therapy for Female Sexual Dysfunction“. Sexual Medicine Reviews 3, Nr. 3 (Juli 2015): 137–44. http://dx.doi.org/10.1002/smrj.53.
Der volle Inhalt der Quelle
44
McHugh, D. J., R. W. Birch, M. A. Zanetos, T. Ali und G. W. Waylonis. „SEXUAL DYSFUNCTION ASSOCIATED WITH FIBROMYALGIA“. American Journal of Physical Medicine & Rehabilitation 72, Nr. 4 (August 1993): 235. http://dx.doi.org/10.1097/00002060-199308000-00023.
Der volle Inhalt der Quelle
45
Khan, Fary, Julie F. Pallant, Louisa Ng und Michael Whishaw. „Sexual Dysfunction in Multiple Sclerosis“. Sexuality and Disability 29, Nr. 2 (23.01.2011): 101–11. http://dx.doi.org/10.1007/s11195-011-9198-4.
Der volle Inhalt der Quelle
46
Yoon, Hana. „Hormone Replacement Therapy in Female Sexual Dysfunction“. Korean Journal of Andrology 30, Nr. 1 (2012): 13. http://dx.doi.org/10.5534/kja.2012.30.1.13.
Der volle Inhalt der Quelle
47
Colson, Amy E., Marla J. Keller, Paul E. Sax, Parker T. Pettus, Richard Platt und Peter W. Choo. „Male Sexual Dysfunction Associated With Antiretroviral Therapy“. JAIDS Journal of Acquired Immune Deficiency Syndromes 30, Nr. 1 (Mai 2002): 27–32. http://dx.doi.org/10.1097/00042560-200205010-00004.
Der volle Inhalt der Quelle
48
Colson, Amy E., Marla J. Keller, Paul E. Sax, Parker T. Pettus, Richard Platt und Peter W. Choo. „Male Sexual Dysfunction Associated With Antiretroviral Therapy“. JAIDS Journal of Acquired Immune Deficiency Syndromes 30, Nr. 1 (Mai 2002): 27–32. http://dx.doi.org/10.1097/00126334-200205010-00004.
Der volle Inhalt der Quelle
49
Tenfelde, Sandi, Dana Hayden und Jeffrey Albaugh. „Sexual Dysfunction and Intimacy for Ostomates“. Clinics in Colon and Rectal Surgery 30, Nr. 03 (22.05.2017): 201–6. http://dx.doi.org/10.1055/s-0037-1598161.
Der volle Inhalt der QuelleAnnotation:
AbstractSex and intimacy presents special challenges for the ostomate. Since some colorectal surgery patients will require either temporary or permanent stomas, intimacy and sexuality is a common issue for ostomates. In addition to the stoma, nerve damage, radiotherapy, and chemotherapy are often used in conjunction with stoma creation for cancer patients, thereby adding physiological dysfunction to the personal psychological impact of the stoma, leading to sexual dysfunction. The purpose of this paper is to describe the prevalence, etiology, and the most common types of sexual dysfunction in men and women after colorectal surgery and particularly those patients with stomas. In addition, treatment strategies for sexual dysfunction will also be described.
50
Dorevitch, Abraham, und Hillel Davis. „Fluvoxamine-Associated Sexual Dysfunction“. Annals of Pharmacotherapy 28, Nr. 7-8 (Juli 1994): 872–74. http://dx.doi.org/10.1177/106002809402800709.
Der volle Inhalt der QuelleAnnotation:
OBJECTIVE: To report two cases of sexual dysfunction induced by fluvoxamine, a selective serotonin reuptake inhibitor (SSRI). SETTING: University teaching hospital. PATIENTS: Two depressed patients who developed ejaculation and orgasmic difficulties after initiation of fluvoxamine therapy. DISCUSSION: The literature concerning sexual dysfunction with serotonergic antidepressants is reviewed, and speculated mechanisms for this untoward effect are discussed. CONCLUSIONS: Sexual dysfunction associated with antidepressant drugs, including SSRIs, may be underreported. This troublesome adverse effect may significantly affect patient comfort and compliance. Careful evaluation of sexual function is warranted, prior to and during drug treatment, especially as more serotonergic antidepressant agents become available.